MUSTANG BIO, INC. MBIO Cash Flow

Mustang bio, inc. (MBIO)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16
Cash Flows from Operating Activities:
Net loss
-48,633	-46,389	-41,950	-39,300	-33,994	-30,662	-34,493	-33,915	-34,351	-31,288	-24,435	-19,365	-14,969	-12,654	0	0	0
Issuance of common shares - Equity fee on At-the-Market Offering to Fortress Biotech
620	495	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech
0	375	375	375	375	0	0	0	0	-	-	-	-	-	-	-	-
Research and development - licenses acquired
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Research and development - licenses acquired
1,150	1,350	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation expenses
3,037	2,664	3,265	3,048	3,397	4,960	4,651	4,581	4,007	2,012	0	0	0	-	-	-	-
Depreciation expense
1,400	1,300	1,200	1,100	893	600	302	102	9	2	0	0	0	-	-	-	-
Research and development - licenses acquired
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Research and development - licenses acquired
-	-	-	-	-	-	-	-	-	2,875	2,375	2,075	575	0	0	0	0
Issuance of common shares - Founders Agreement
-	-	-	-	-	-	-	-	-	1,234	1,822	2,094	2,094	862	0	0	0
Accretion of debt discount
969	710	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating lease right-of-use assets
111	110	80	65	30	0	0	0	0	-	-	-	-	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
0	-	-	-	0	-	-	-	-	-	0	0	0	-	-	-	-
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Interest receivables
-	-	-	-	-	-	-	-	-	106	0	0	0	-	-	-	-
Other receivables - related party
-97	19	5	128	111	0	0	0	0	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-	-	-	-	-	-	546	-808	662	1,332	1,566	2,652	435	668	0	0	0
Payable and accrued expenses - related party
-72	360	9	572	302	99	206	49	301	12	-681	-487	-485	-250	0	0	0
Accrued interest - related party
-	-	-	-	-	-	-	-	-	-413	-446	-342	-247	245	0	0	0
Deferred rent
-	-	-	-	-	-691	-470	-395	-125	-50	0	0	0	-	-	-	-
Lease liabilities
-381	-53	-101	28	12	0	0	0	0	-	-	-	-	-	-	-	-
Notes payable - related party
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0
Net cash used in operating activities
-37,250	-33,581	-30,614	-25,584	-20,162	-19,244	-17,888	-18,859	-16,477	-12,948	0	0	0	-	-	-	-
Cash Flows from Investing Activities:
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Purchase of short-term investment (certificates of deposit)
-	-	-	-	-	52,500	59,414	60,964	71,002	46,002	0	0	0	-	-	-	-
Maturity of certificate of deposit
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Maturity of certificate of deposit
-	-	-	-	-	-	-	46,002	34,000	20,000	0	0	0	-	-	-	-
Purchase of research and development licenses
1,150	1,350	850	1,450	1,200	1,075	1,075	1,875	2,075	2,375	2,375	575	375	0	0	0	0
Purchase of fixed assets
2,572	2,345	1,758	2,407	6,493	6,870	0	0	0	-	-	-	-	-	-	-	-
Purchase of fixed assets - construction-in-process
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Net cash provided by investing activities
1,382	13,909	19,996	31,247	24,309	557	3,294	-22,930	-40,428	-29,052	0	0	0	-	-	-	-
Cash Flows from Financing Activities:
Proceeds from Horizon Notes
1,387	15,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Fortress Note
-	-	-	-	-	-	-	-	-	-	-	-	-	2,221	0	0	0
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Payment of Fortress Note
-	-	-	-	-	-	-	-	-	320	-1,212	2,321	2,321	2,001	0	0	0
Proceeds from Horizon Note, net of debt discount
-	-	-	-	-	-	-	-	54	50,296	74,221	85,242	85,250	35,008	0	0	0
Proceeds from exercise of warrants
0	0	0	0	85	181	181	181	96	0	0	0	0	-	-	-	-
Proceeds from issuance of common shares - At-the-Market Offering
27,512	22,515	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Offering costs for the issuance of common shares - At-the-Market Offering
630	543	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common shares under ESPP
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
56,582	65,116	65,116	65,227	13,698	181	181	243	150	49,976	0	0	0	-	-	-	-
Net change in cash, cash equivalents and restricted cash
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net change in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-41,546	-56,755	7,976	0	0	0	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Net change in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Supplemental disclosure of cash flow information:
Cash paid for interest
1,398	1,057	698	341	0	0	0	0	0	413	0	0	0	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Supplemental disclosure of noncash investing and financing activities:
Fixed assets (acquired but not paid)
536	187	359	-439	-1,933	196	0	0	0	-	-	-	-	-	-	-	-
Construction-in-progress included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Issuance of common shares - Founders Agreement
4,923	2,085	2,085	2,085	2,085	9,558	9,558	9,558	9,558	4,396	4,396	4,396	4,396	190	0	0	0
Research and development licenses included in accounts payable and accrued expenses
0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Research and development licenses included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Issuance of warrants - Horizon Notes
0	888	888	888	888	0	0	0	0	-	-	-	-	-	-	-	-
Common shares issuable for license acquired
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Common shares issuable for license acquired
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0